Cite
Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome.
MLA
Urbanek, Konrad, et al. “Dapagliflozin Protects the Kidney in a Non-Diabetic Model of Cardiorenal Syndrome.” Pharmacological Research, vol. 188, Feb. 2023, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.phrs.2023.106659.
APA
Urbanek, K., Cappetta, D., Bellocchio, G., Coppola, M. A., Imbrici, P., Telesca, M., Donniacuo, M., Riemma, M. A., Mele, E., Cianflone, E., Naviglio, S., Conte, E., Camerino, G. M., Mele, M., Bucci, M., Castaldo, G., De Luca, A., Rossi, F., Berrino, L., & Liantonio, A. (2023). Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome. Pharmacological Research, 188, N.PAG. https://doi.org/10.1016/j.phrs.2023.106659
Chicago
Urbanek, Konrad, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, et al. 2023. “Dapagliflozin Protects the Kidney in a Non-Diabetic Model of Cardiorenal Syndrome.” Pharmacological Research 188 (February): N.PAG. doi:10.1016/j.phrs.2023.106659.